ArticleMolecular biology reports2025
A miR-770-5p/XBP1-driven pathway controls ESR1 expression and tamoxifen response in luminal breast cancer.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regulatory Mechanisms of XBP1 in Tumorigenesis and Cancer Progression: Challenges and Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Functional foods and exercise in breast cancer: epigenetic modulation, chemotherapy tolerance, and fatigue management.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer cells employ various adaptive mechanisms to withstand stressors, with one notable pathway being the unfolded protein response (UPR), crucial in fostering endocrine resistance within ER-positive breast cancer. Investigating miRNAs within tumors holds promise for identifying key miRNA-gene interactions pivotal for tumor characteristics like proliferation and resistance to treatment. Notably, XBP1 emerges as a pivotal player in UPR within the endoplasmic reticulum, particularly through the inositol-requiring enzyme 1 (IRE1α) - the X-box-binding protein 1 (XBP1) pathway, presenting a compelling target for clinical intervention. In this study, I explore the regulatory role of miR-770-5p in modulating XBP1 expression and its potential as a therapeutic target in luminal breast cancer. METHODS AND
resultsThe role of XBP1 in cancer cell pathogenesis has been investigated using bioinformatics tools to analyze its expression in breast cancer samples and its association with clinical outcomes. The relationship between miR-770-5p and XBP1 was further explored through bioinformatics analysis and ROC plot assessment. qRT-PCR and bioinformatics data confirmed the negative correlation between miR-770-5p and XBP1, particularly in Luminal A subtype with wild-type p53. My results demonstrated that miR-770-5p targets XBP1, inhibiting its spliced form and reducing its downstream transcriptional activity. Moreover, I found that miR-770-5p can modulate tamoxifen sensitivity by influencing the XBP1/ESR1 axis in breast cancer cells. Overexpression of miR-770-5p led to decreased ESR1 levels, enhancing tamoxifen efficacy and suggesting a potential novel therapeutic approach for luminal subtype breast cancer.
conclusionsmiR-770-5p has a growth-inhibitory function in luminal breast cancer, where its suppression of XBP1 contributes to the increased sensitivity to tamoxifen.
Indexed as
Identifiers
40407833What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.